Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Striatopallidal neurons are selectively protected by neurturin in an excitotoxic model of Huntington's disease.

Marco S, Pérez-Navarro E, Tolosa E, Arenas E, Alberch J.

J Neurobiol. 2002 Mar;50(4):323-32.

PMID:
11891666
2.

Neurturin protects striatal projection neurons but not interneurons in a rat model of Huntington's disease.

Pérez-Navarro E, Akerud P, Marco S, Canals JM, Tolosa E, Arenas E, Alberch J.

Neuroscience. 2000;98(1):89-96.

PMID:
10858615
3.

Intrastriatal grafting of a GDNF-producing cell line protects striatonigral neurons from quinolinic acid excitotoxicity in vivo.

Pérez-Navarro E, Arenas E, Marco S, Alberch J.

Eur J Neurosci. 1999 Jan;11(1):241-9.

PMID:
9987028
4.

Neuroprotection by neurotrophins and GDNF family members in the excitotoxic model of Huntington's disease.

Alberch J, Pérez-Navarro E, Canals JM.

Brain Res Bull. 2002 Apr;57(6):817-22. Review.

PMID:
12031278
5.

Lithium suppresses excitotoxicity-induced striatal lesions in a rat model of Huntington's disease.

Wei H, Qin ZH, Senatorov VV, Wei W, Wang Y, Qian Y, Chuang DM.

Neuroscience. 2001;106(3):603-12.

PMID:
11591460
6.

Quinolinic acid-induced increases in calbindin D28k immunoreactivity in rat striatal neurons in vivo and in vitro mimic the pattern seen in Huntington's disease.

Huang Q, Zhou D, Sapp E, Aizawa H, Ge P, Bird ED, Vonsattel JP, DiFiglia M.

Neuroscience. 1995 Mar;65(2):397-407.

PMID:
7777157
8.
9.
10.

The IGF-I amino-terminal tripeptide glycine-proline-glutamate (GPE) is neuroprotective to striatum in the quinolinic acid lesion animal model of Huntington's disease.

Alexi T, Hughes PE, van Roon-Mom WM, Faull RL, Williams CE, Clark RG, Gluckman PD.

Exp Neurol. 1999 Sep;159(1):84-97.

PMID:
10486177
12.

Expression of NMDA receptor subunit mRNAs in neurochemically identified projection and interneurons in the human striatum.

Küppenbender KD, Standaert DG, Feuerstein TJ, Penney JB Jr, Young AB, Landwehrmeyer GB.

J Comp Neurol. 2000 Apr 17;419(4):407-21.

PMID:
10742712
13.
14.

The 1993 Upjohn Award Lecture. Quinolinic acid induced brain neurotransmitter deficits: modulation by endogenous excitotoxin antagonists.

Jhamandas KH, Boegman RJ, Beninger RJ.

Can J Physiol Pharmacol. 1994 Dec;72(12):1473-82. Review.

PMID:
7736338
16.

Neurogenesis in the striatum of the quinolinic acid lesion model of Huntington's disease.

Tattersfield AS, Croon RJ, Liu YW, Kells AP, Faull RL, Connor B.

Neuroscience. 2004;127(2):319-32.

PMID:
15262322
17.

Reduced expression of preproenkephalin in striatal neurons from Huntington's disease patients.

Richfield EK, Maguire-Zeiss KA, Cox C, Gilmore J, Voorn P.

Ann Neurol. 1995 Mar;37(3):335-43.

PMID:
7695232
18.
19.

Protective effect of encapsulated cells producing neurotrophic factor CNTF in a monkey model of Huntington's disease.

Emerich DF, Winn SR, Hantraye PM, Peschanski M, Chen EY, Chu Y, McDermott P, Baetge EE, Kordower JH.

Nature. 1997 Mar 27;386(6623):395-9.

PMID:
9121555
20.

Cellular delivery of human CNTF prevents motor and cognitive dysfunction in a rodent model of Huntington's disease.

Emerich DF, Cain CK, Greco C, Saydoff JA, Hu ZY, Liu H, Lindner MD.

Cell Transplant. 1997 May-Jun;6(3):249-66.

PMID:
9171158

Supplemental Content

Support Center